Atria Investments Inc Acquires 4,637 Shares of Becton, Dickinson and Company $BDX

Atria Investments Inc boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 24.5% in the second quarter, Holdings Channel.com reports. The firm owned 23,554 shares of the medical instruments supplier’s stock after purchasing an additional 4,637 shares during the quarter. Atria Investments Inc’s holdings in Becton, Dickinson and Company were worth $4,057,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of BDX. Saudi Central Bank acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $26,000. Cornerstone Planning Group LLC increased its holdings in Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares in the last quarter. Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $31,000. Bank of Jackson Hole Trust increased its holdings in Becton, Dickinson and Company by 85.6% in the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 95 shares in the last quarter. Finally, WPG Advisers LLC acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $36,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the subject of several recent research reports. Royal Bank Of Canada reissued a “sector perform” rating and issued a $211.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, October 16th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Morgan Stanley increased their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Piper Sandler reissued a “neutral” rating and issued a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, Wells Fargo & Company increased their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Stock Down 0.3%

Shares of Becton, Dickinson and Company stock opened at $178.77 on Friday. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The stock’s 50-day moving average is $188.38 and its 200 day moving average is $183.04. The firm has a market cap of $51.24 billion, a price-to-earnings ratio of 32.15, a PEG ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.32 billion for the quarter. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Insider Activity at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 1,895 shares of company stock worth $358,995. 0.36% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.